The Fred Hutchinson/University of Washington Cancer Consortium is a collaboration among four partner institutions: the Fred Hutchinson Cancer Research Center, the University of Washington, Seattle Children's Hospital, and the Seattle Cancer Care Alliance (SCCA).

During the past decade, Fred Hutch/University of Washington Cancer Consortium conducted 255 clinical trials. In the 10-year time frame, 255 clinical trials started and 205 clinical trials were completed, i.e. on average, 80.4% percent of trials that started reached the finish line to date. In the past 5 years, 129 clinical trials started and 84 clinical trials were completed. i.e. 65.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fred Hutch/University of Washington Cancer Consortium" #1 sponsor was "Fred Hutchinson Cancer Center" with 258 trials, followed by "University of Washington" with 190 trials sponsored, "National Cancer Institute (NCI)" with 16 trials sponsored, "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium" with 6 trials sponsored and "Nohla Therapeutics, Inc." with 6 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fred Hutch/University of Washington Cancer Consortium" #1 collaborator was "National Cancer Institute (NCI)" with 353 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 35 trials as a collaborator, "AstraZeneca" with 11 trials as a collaborator, "National Institutes of Health (NIH)" with 8 trials as a collaborator and "Merck Sharp & Dohme LLC" with 6 trials as a collaborator. Other collaborators include 135 different institutions and companies that were collaborators in the rest 96 trials.

According to Clinical.Site data, the most researched conditions in "Fred Hutch/University of Washington Cancer Consortium" are "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities" (44 trials), "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)" (43 trials), "Recurrent Adult Acute Myeloid Leukemia" (43 trials), "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)" (41 trials) and "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)" (41 trials). Many other conditions were trialed in "Fred Hutch/University of Washington Cancer Consortium" in a lesser frequency.

Most popular intervention types in "Fred Hutch/University of Washington Cancer Consortium" are "Drug" (340 trials), "Other" (317 trials), "Biological" (215 trials), "Procedure" (203 trials) and "Radiation" (126 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (135 trials), "laboratory biomarker analysis" (75 trials), "Questionnaire Administration" (65 trials), "Total-Body Irradiation" (51 trials) and "Cyclophosphamide" (48 trials). Other intervention names were less common.

The vast majority of trials in "Fred Hutch/University of Washington Cancer Consortium" are 434 trials for "All" genders, 39 trials for "Female" genders and 26 trials for "Male" genders.

Currently, there are 145 active trials in "Fred Hutch/University of Washington Cancer Consortium". 7 are not yet recruiting, 90 are recruiting, 44 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 245 completed trials in Fred Hutch/University of Washington Cancer Consortium, 6 suspended trials, and 81 terminated clinical trials to date.

Out of the total trials that were conducted in Fred Hutch/University of Washington Cancer Consortium, 159 "Phase 1" clinical trials were conducted, 282 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 90 trials that are defined as “Not Applicable".